Close Menu

NEW YORK – Clinical-stage biotech company Bridge Biotherapeutics said last week that its investigational new drug application for BBT-176 was accepted by South Korea's Ministry of Food and Drug Safety, allowing it to start clinical trials.

BBT-176 is a tyrosine kinase inhibitor designed to interrupt the EGFR signaling pathway perturbed by C797S mutations. Non-small cell lung cancer patients with EGFR C797S mutations tend to be resistant to the third-generation TKI osimertinib (AstraZeneca's Tagrisso).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.